Thymidylate synthase inhibitor
From Wikipedia, the free encyclopedia
Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme thymidylate synthase and have potential as an anticancer chemotherapy.[1] Five agents were in clinical trials in 2002: raltitrexed, pemetrexed, nolatrexed, ZD9331, and GS7904L.[2]
Examples include
- Raltitrexed, used for colorectal cancer since 1998
- Fluorouracil, used for colorectal cancer[3]
- BGC 945[4]
[edit] References
- ^ Jackman, A.L.; Calvert, A.H. (1995). "Folate-based thymidylate synthase inhibitors as anticancer drugs". Annals of Oncology 6 (9): 871–881. http://annonc.oxfordjournals.org/content/6/9/871.abstract.
- ^ "Thymidylate synthase inhibitors as anticancer agents: from bench to bedside". http://cat.inist.fr/?aModele=afficheN&cpsidt=15072905+. Retrieved 2009-01-28.
- ^ Papamichael, D. (1999). "The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status". Oncologist 4 (6): 478–87. PMID 10631692. http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=10631692.
- ^ Gibbs, David D., et al (2005). "BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors". Cancer Research 65 (24): 11721–11728. doi:10.1158/0008-5472.CAN-05-2034. http://cancerres.aacrjournals.org/content/65/24/11721.abstract.
|
|||||||||||||||||||
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
